Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zolmitriptan
Drug ID BADD_D02393
Description Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. It is currently available in both tablet and nasal spray forms.[L12978]
Indications and Usage Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.[L12978]
Marketing Status approved; investigational
ATC Code N02CC03
DrugBank ID DB00315
KEGG ID D00415
MeSH ID C089750
PubChem ID 60857
TTD Drug ID D0NG7O
NDC Product Code 64567-0016; 63548-0101; 64896-681; 64896-682; 64980-256; 68001-250; 72189-435; 65372-1145; 16571-803; 69238-2007; 65977-0050; 67835-5007; 64896-692; 65841-765; 65841-766; 64896-691; 64980-204; 69097-864; 71626-101; 72189-434; 65015-688; 46708-182; 64896-672; 68001-249; 68462-498; 60846-2384; 64896-671; 64980-203; 64980-257; 65841-768; 68382-715; 68462-497; 69097-863; 63548-0102; 63629-9575; 68382-712; 72606-567; 54864-955; 27241-022; 68382-717; 68462-499; 11722-012; 63850-4322; 45802-711; 46708-181; 46708-463; 55700-943; 55700-944; 68382-714; 69238-2006; 55111-800; 27241-021; 46708-462; 60846-2383; 65841-767; 65862-914; 65862-915; 68462-500; 71626-102; 72606-568; 65862-801; 66039-845; 16571-804
UNII 2FS66TH3YW
Synonyms zolmitriptan | 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | Zomig | AscoTop | Zomigoro | 311C90 | Flezol
Chemical Information
Molecular Formula C16H21N3O2
CAS Registry Number 139264-17-8
SMILES CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual field defect17.17.01.001; 06.02.07.0030.001015%Not Available
Vomiting07.01.07.0030.007853%
Weight increased13.15.01.006--
Yawning22.12.03.037--Not Available
Coronary artery dissection12.02.01.035; 24.02.02.001; 02.02.01.0040.000677%Not Available
Muscle tightness15.05.03.0070.000677%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.001692%Not Available
Nasal discomfort22.12.03.0120.001489%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000677%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Vasodilation procedure25.03.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.0010.000677%
Cardiac disorder02.11.01.0030.000677%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Genitourinary tract neoplasm21.10.02.004; 20.08.01.003; 16.15.01.001--Not Available
Infarction24.04.02.017--Not Available
Decreased appetite08.01.09.028; 14.03.01.0050.002369%
Ill-defined disorder08.01.03.049--Not Available
Drug intolerance08.06.01.013--Not Available
Psychotic disorder19.03.01.002--
Cystitis noninfective20.03.02.001--
Adverse reaction08.06.01.018--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages